NCT02775773 (TRANOXY2016) is a Phase 3 clinical trial of Tranexamic Acid in Post Partum Haemorrhage, sponsored by Azienda U.S.L. 1 di Massa e Carrara.

Who is sponsoring NCT02775773?

NCT02775773 is sponsored by Azienda U.S.L. 1 di Massa e Carrara.

What drugs are being tested in NCT02775773?

Interventions in NCT02775773: Tranexamic Acid, Oxytocin.

What condition does NCT02775773 study?

NCT02775773 studies Post Partum Haemorrhage.

Is NCT02775773 still recruiting?

NCT02775773 is currently completed. Last updated 8 February 2024.

Last reviewed 2024-02-08 · How we verify

NCT02775773: TRANOXY2016

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study to Assess the Equivalence of Tranexamic Acid vs Oxytocin in Reducing the PPH

Completed Phase 3 Last updated 8 February 2024

What this trial tests

Phase 3 trial testing Tranexamic Acid in Post Partum Haemorrhage in 256 participants. Completed in 31 December 2018.

Timeline

30 January 2018

Primary endpoint
31 December 2018

31 December 2018

Quick facts

Lead sponsor	Azienda U.S.L. 1 di Massa e Carrara
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	256
Start date	30 January 2018
Primary completion	31 December 2018
Estimated completion	31 December 2018
Sites	1 location across Italy

Drugs / interventions tested

Tranexamic Acid (Tranexamic Acid) — full drug profile →
Oxytocin (OXYTOCIN) — full drug profile →

Conditions studied

Post Partum Haemorrhage — all drugs for Post Partum Haemorrhage →

Sponsor

Azienda U.S.L. 1 di Massa e Carrara

Who can join

Adults 18 to 50, female only, with Post Partum Haemorrhage. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study was to evaluate that the tranexamic acid (TXA)Intravenous and oral, is equivalent oxytocin (OXY),intramuscularly, in reducing the blood loss in post partum period (mL) in patients at the end of pregnancy ( 37-42 w ) at low risk of post partum hemorrhage (PPH). The PPH means a blood loss equal to or greater than 500 ml after a vaginal delivery (the bleeding is defined severe if it exceeds 1000 mL). PPH is called "primary" when blood loss arose within 24 hours after birth.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Tranexamic acid versus oxytocin prophylaxis in reducing post-partum blood loss, in low-risk pregnant women: TRANOXY STUDY, a phase III randomized clinical trial.
Ragusa A, Ficarola F, Ferrari A, Spirito N, et al · · 2024 · cited 3× · PMID 38873634 · DOI 10.1016/j.eclinm.2024.102665

Verify or expand the search:

Other trials of Tranexamic Acid

Trials testing the same drug.

NCT07501884 — REDUCER Trial (TXA in Urethroplasty) · Phase 4 · not yet recruiting
NCT07460518 — Tranexamic Acid for Bleeding Reduction During TURP Surgery · Phase 4 · not yet recruiting
NCT07390799 — Prophylactic Tranexamic Acid in Low-Risk Repeat Cesarean Delivery: A Randomized Controlled Trial · NA · not yet recruiting
NCT07078942 — Prophylactic Intravenous Tranexamic Acid on Perioperative Blood Loss in Pregnant Women Undergoing Cesarean Section · Phase 4 · not yet recruiting
NCT07263841 — Comparison of Effectiveness of Tranexamic Acid Mesotherapy Versus Glutathione Mesotherapy in Post Burn Facial Hyperpigme · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02775773 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Azienda U.S.L. 1 di Massa e Carrara
Last refreshed: 8 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02775773.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing